![Placeholder Image Placeholder Image](https://prod1.novartis.com/us-en/sites/novartis_us/files/placeholder.jpeg)
Tags Archive Navigation
icon
-
Media ReleaseKymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
-
Media ReleaseAlcon Introduces AIR OPTIX® COLORS Contact Lenses Gemstone Collection, Creating New Ways to Enhance and Play with Eye Color
-
Media ReleaseNew Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval
-
Media ReleaseNovartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
-
Media ReleasePhase III data in The Lancet show Novartis siponimod significantly improved outcomes in patients with secondary progressive MS
-
Media ReleaseNovartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis
-
Media ReleaseNovartis receives FDA approval for Cosentyx® label update to include moderate to severe scalp psoriasis
-
Media ReleaseNovartis new data reinforces superiority of Cosentyx® versus Stelara® in achieving skin clearance for psoriasis patients
-
Media ReleaseNovartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
-
Media ReleaseNovartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
-
Media ReleaseNovartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
-
Media ReleaseNovartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study
Pagination
- ‹ Previous page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- …
- 49
- › Next page